Dacsted 200mg Injection (Dacarbazine)

Dacsted 200 mg Injection is a prescription drug that contains dacarbazine. The medicine is available in form of a 200 mg injection and falls in the class of antineoplastic medicines known as cytotoxic antineoplastic agents. Dacarbazine 200mg Injection is indicated for the treatment of metastatic malignant melanoma and may also be combined with other cancer medicines in specific regimens for the treatment of Hodgkin lymphoma.

Despite its continued use, dacarbazine Injection has been overtaken by immunotherapy and newer target therapies in certain cases. Dacsted 200 mg Injection is classified as a prodrug, implying that it requires conversion by the body to active components, predominantly in the liver. The active components interfere with the multiplication of vulnerable cancer cells by damaging their DNA. It comes in the strength of 200 mg, referring to the injection preparation; however, this does not necessarily indicate the whole dosage prescribed to the patient. The dosage and duration of treatment are influenced by several factors, including type of cancer, treatment regimen, organ functions, other drugs, and the tolerance of the treatment by the patient.

Dacsted 200mg Injection may be prescribed in the following established clinical settings. The exact treatment line, combination regimen and duration depend on the diagnosis, current labeling and specialist assessment.
Metastatic malignant melanoma: dacarbazine 200mg has an established regulatory indication, although modern immunotherapy and molecularly targeted treatments have changed its contemporary role.
Hodgkin lymphoma: dacarbazine Injection is indicated as second-line therapy in combination with other effective agents under U.S. labeling and is also a component of recognized multi-agent lymphoma regimens.

It is classified as a prodrug, meaning that the drug must be activated in the liver to become toxic substances that will harm the cancer cell DNA, thus making cell division impossible. The damaged DNA will lead to the death of vulnerable cancer cells.

• The clinical information given above pertains to dacarbazine Injection and the regimen in which it is used and not to the Dacsted 200mg Injection itself.
  
• Dacarbazine 200mg Injection has been in use for several decades as a treatment option for metastatic melanoma, despite the availability of other drugs reducing its usage in some patients.
  
• Dacarbazine 200mg is still administered in combination chemotherapy for the treatment of Hodgkin lymphoma. The advantages and disadvantages of the drug need to be weighed against the entire regimen.
  
• The available evidence is for the medicine dacarbazine Injection and the regimen in which it is used, rather than clinical trial evidence specific to the medicine brand.
  
  

The side effects of Dacarbazine Injection vary by indication, dose, treatment duration, concomitant medicines and individual patient factors. Common or clinically relevant effects include:

• Nausea
  
• Vomiting
  
• Leukopenia
  
• Thrombocytopenia
  
• Anemia
  
• Flu-like symptoms
  
• Loss of appetite
  
• Alopecia
  
• Facial flushing or paresthesia
  
• Occasional rash/photosensitivity

Serious or persistent symptoms should be assessed promptly. The treating team should provide medicine-specific instructions on which symptoms require urgent medical attention.

Dacsted Injection is administered in a healthcare setting. There is no single universal 200mg patient dose. These are molecule-level examples from regulatory labeling or established product information and are not instructions for self-dosing. The treating specialist determines the actual dose, schedule, dose modifications and supportive medicines.

Dacsted 200mg is given according to a scheduled treatment plan. If an appointment or dose is missed or delayed, contact the treating team promptly. Do not attempt to compensate for a missed Dacarbazine Injection dose or alter the treatment cycle without medical advice.

Monitoring is individualized according to the disease and treatment regimen. It may include:

• CBC
  
• Liver-function tests
  
• Renal function when clinically indicated
  
• Nausea/vomiting and hydration
  
• Infection and bleeding
  
• Infusion site
  
• Disease-specific response
  

1. DailyMed. Dacarbazine for Injection prescribing information, updated 2025 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6b97e41-5f15-498c-abfb-d8443ea4d216​
2. Disease-specific oncology guidelines https://www.nccn.org/guidelines/category_1​
3. Current India-specific Dacsted package insert should be checked before publication https://www.researchgate.net/publication/391126980_Analysis_of_the_drug_package_inserts_in_India_as_per_the_CDSCO_guidelines​
4. National Cancer Institute (NCI). Dacarbazine Drug Information. Cancer.gov. Https://www.cancer.gov/about-cancer/treatment/drugs/dacarbazine​
5. National Cancer Institute (NCI). Adult Hodgkin Lymphoma Treatment (PDQ®). Cancer.gov https://www.cancer.gov/types/lymphoma/patient/adult-hodgkin-treatment-pdq​